Nemaura Medical secures $10M non-dilutive credit facility

Nemaura Medical announced the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company’s strategic growth plans. Recognizing the challenges associated with equity sales, particularly in the small-cap landscape on the Nasdaq, Nemaura Medical has proactively pursued a funding strategy that minimizes dilution and, the Company believes, aligns with the best interests of its valued shareholders. This $10 million credit facility, structured to be non-dilutive, empowers the Company to draw down a maximum of $1 million per month, providing a steady and controlled infusion of capital to support Nemaura Medical’s commercialization initiatives. The decision to opt for a non-dilutive funding source underscores the Company’s commitment to preserving shareholder value in the current market conditions. Dilution has long been a concern for public companies, and the Company believes that this credit facility not only addresses this concern but also positions Nemaura Medical for strategic growth.